Bladder perfusion pharmaceutical composition, preparation method therefor and application thereof
US-2024398841-A1 · Dec 5, 2024 · US
Agent for overcoming immunosuppression and use thereof
US2019038645A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2019038645-A1 |
| Application number | US-201716073871-A |
| Country | US |
| Kind code | A1 |
| Filing date | Feb 15, 2017 |
| Priority date | Feb 16, 2016 |
| Publication date | Feb 7, 2019 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
First claim
Opening claim text (preview).
1 - 16 . (canceled) 17 : A method for overcoming immunosuppression, the method comprising administering an effective amount of an anthracycline antibiotic to a patient. 18 : A method for inhibiting FOXP3 function, the method comprising administering an effective amount of an anthracycline antibiotic to a patient. 19 : The method of claim 17 , wherein the anthracycline antibiotic is one or more selected from the group consisting of epirubicin, doxorubicin, pirarubicin, daunorubicin, idarubicin, and a salt thereof. 20 : The method of claim 17 , wherein the anthracycline antibiotic is epirubicin or a salt thereof. 21 : The method of claim 17 , wherein the anthracycline antibiotic is administered at a lower dose than a dose having cytotoxicity against cancer cells. 22 : The method of claim 17 , wherein the anthracycline antibiotic is administered at a lower dose than a dose having cytotoxicity against at least one selected from the group consisting of a solid cancer and a blood cancer. 23 : The method of claim 17 , wherein the anthracycline antibiotic is administered in a range of 0.01 to 1 mg/kg per day. 24 : The method of claim 17 , wherein the anthracycline antibiotic is administered in a range of 1/100 to ⅘ of a dose having cytotoxicity against at least one selected from the group consisting of a solid cancer and a blood cancer. 25 : The method of claim 17 , further comprising another anticancer therapy. 26 : The method of claim 25 , wherein the another anticancer therapy is a cancer chemotherapy or a cancer immunotherapy. 27 : The method of claim 26 , wherein the cancer immunotherapy is an immune checkpoint blockade therapy, a cancer vaccine therapy, or a T cell transfer therapy. 28 : The method of claim 18 , wherein the anthracycline antibiotic is one or more selected from the group consisting of epirubicin, doxorubicin, pirarubicin, daunorubicin, idarubicin, and a salt thereof. 29 : The method of claim 18 , wherein the anthracycline antibiotic is epirubicin or a salt thereof. 30 : The method of claim 18 , wherein the anthracycline antibiotic is administered at a lower dose than a dose having cytotoxicity against cancer cells. 31 : The method of claim 18 , wherein the anthracycline antibiotic is administered at a lower dose than a dose having cytotoxicity against at least one selected from the group consisting of a solid cancer and a blood cancer. 32 : The method of claim 18 , wherein the anthracycline antibiotic is administered in a range of 0.01 to 1 mg/kg per day. 33 : The method of claim 18 , wherein the anthracycline antibiotic is administered in a range of 1/100 to ⅘ of a dose having cytotoxicity against at least one selected from the group consisting of a solid cancer and a blood cancer. 34 : The method of claim 18 , further comprising another anticancer therapy. 35 : The method of claim 34 , wherein the another anticancer therapy is a cancer chemotherapy or a cancer immunotherapy. 36 : The method of claim 35 , wherein the cancer immunotherapy is an immune checkpoint blockade therapy, a cancer vaccine therapy, or a T cell transfer therapy.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Immunomodulators · CPC title
- A61K31/704Primary
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title
Antineoplastic agents · CPC title
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2019038645A1 cover?
- To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
- Who is the assignee on this patent?
- General Incorporated Ass Pharma Valley Project Supporting Organization, Yakult Honsha Kk
- What technology area does this patent fall under?
- Primary CPC classification A61K31/704. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Feb 07 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).